osimertinib resistance in non-small cell lung cancer: pathways and potential solutions
Published 1 year ago • 2.7K plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:02
osimertinib for treating non-small cell lung cancer
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
5:52
mechanisms of osimertinib resistance in aura 3
-
0:48
laura trial - osimertinib as consolidation in non-small cell lung cancer.
-
2:02
understanding egfr resistance in patients with met-amplified nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
5:42
osimertinib and the flaura trial
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
5:52
treatment of egfr nsclc after osimertinib
-
1:56
counteracting non-small cell lung cancer’s resistance to radiation therapy
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc